4:16 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Preclinical News

Synlogic engineers E. coli to treat solid tumors

Synlogic Inc. (NASDAQ:SYBX) presented a pair of posters at the American Association for Cancer Research meeting in Chicago showing that E. coli Nissle genetically engineered to promote T cell activity could help treat solid tumors.

Tumors can generate an immunosuppressive microenvironment through the production of metabolites, such as adenosine and kynurenine, that leads to T cell dysfunction and exhaustion. Therapies that enhance T...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >